Automated insulin delivery
Hybrid closed-loop systems that adjust insulin automatically.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 33, 44, 52, 49, 51.
New guidelines and consensus this year
- Continuous Intraperitoneal Insulin Infusion for People With Type 1 Diabetes: A Literature Review and International Position StatementDiabetes Obes Metab2026 Oct
- An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adultsDiabetologia2026 Sep 22
- An International Position Statement on Practical Approaches for Inpatient Continuous Glucose Monitoring, Insulin Pumps, and Automated Insulin Delivery Systems in AdultsDiabetes Care2026 Sep 22
- 2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress among adults with type 1 diabetes or type 2 diabetesDiabetologia2026 Sep 15
- American Association of Clinical Endocrinology Consensus Statement: Use of Diabetes Technology for Management of Adults with DiabetesEndocr Pract2026 Sep 8
All papers from the last 12 months
641 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Glucagon enhances subcutaneous insulin absorption: Pilot experiments in pigsCurr Ther Res Clin Exp2026 DecPMID 42866444
- Optimizing the use of the Omnipod 5 system in adults with type 1 diabetes: an Italian expert Delphi consensusDiabetes Res Clin Pract2026 NovPMID 42772375
- Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension StudyDiabetes Obes Metab2026 NovPMID 42675550RCT
- Transitioning From Sensor-Augmented Insulin Pumps to Hybrid Closed-Loop Systems and the Risk of Progression of Diabetic Retinopathy in Type 1 DiabetesDiabetes Obes Metab2026 NovPMID 42660865
- Real-World Glycemic Outcomes of Open-Source Automated Insulin Delivery During 12 Months Among People With Type 1 Diabetes Across Age GroupsDiabetes Obes Metab2026 NovPMID 42660857
- Priorities, Expectations, Perceptions of Time in Tight Range and Support Needs Relating to Closed-Loop Therapy Among Adults With Type 1 Diabetes: The SELECT HCL StudyDiabetes Obes Metab2026 NovPMID 42638201
- Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost-Effectiveness Analysis in Adults With T1D From a Payer Perspective in SwedenDiabetes Obes Metab2026 NovPMID 42605543
- An Observational Study on the Impact of Menstrual Cycle Phases on Carbohydrate Intake, Insulin Delivery and Glycaemia in Women With Type 1 Diabetes Using MiniMed 780G Automated Insulin Delivery SystemDiabetes Obes Metab2026 NovPMID 42605527
- Comparative Efficacy of Insulin Delivery Modalities on Glycaemic Control in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisDiabetes Obes Metab2026 NovPMID 42443590Systematic review
- Clinical characteristics and in-hospital mortality among insulin pump users with acute coronary syndrome in the predominantly open-loop era: A UK-wide MINAP registry analysisDiabet Med2026 NovPMID 42393932
More endocrinology trends
All specialties →Tirzepatide
A dual GIP/GLP-1 receptor agonist for diabetes and obesity.
Next-generation incretin drugs
Triple agonists and amylin combinations such as retatrutide and CagriSema.
Key point: CagriSema led to a greater proportion of adults with obesity achieving BMI and waist-to-height ratio targets than semaglutide, cagrilintide, or placebo.
Oral GLP-1 drugs
Oral semaglutide and small-molecule GLP-1 agonists such as orforglipron.
Key point: In adults with obesity or overweight and type 2 diabetes, once-daily orforglipron reduced bodyweight versus placebo, with safety similar to other GLP-1 agonists.
Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"automated insulin delivery"[tiab] OR "hybrid closed-loop"[tiab] OR "artificial pancreas"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.